Edesa Biotech reports developments as a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases. Its recurring news centers on paridiprubart, or EB05, an anti-TLR4 antibody evaluated for Acute Respiratory Distress Syndrome, and EB06, an anti-CXCL10 monoclonal antibody program for moderate-to-severe nonsegmental vitiligo.
Company updates also cover clinical data presentations, manufacturing and regulatory preparation, government-supported research activities, conference participation, operating results, capital-structure matters and shareholder governance. Financial reports generally frame spending around clinical development priorities and the company’s monoclonal antibody pipeline.
Edesa Biotech, Inc. (NASDAQ:EDSA) reported its financial results for Q1 2023, ending December 31, 2022. The U.S. FDA granted Fast Track designation for its drug candidate, EB05, aimed at Acute Respiratory Distress Syndrome (ARDS), following favorable Phase 2 results. Edesa achieved positive topline results from a Phase 2b study of EB01 for Allergic Contact Dermatitis, showing significant efficacy. Additionally, Canadian regulators authorized a Phase 2 study for EB06, targeting vitiligo. The company reduced operating expenses by over 50% year-over-year to $2.38 million. Edesa reported a net loss of $2.33 million or $0.13 per share, an improvement from the previous year's loss.
Edesa Biotech (NASDAQ:EDSA) announced the approval from Health Canada for a Phase 2 clinical study of its monoclonal antibody candidate, EB06, targeting vitiligo, a widespread autoimmune condition affecting 1% of the global population. The study aims to evaluate the safety and efficacy of EB06 versus placebo in approximately 120 adults with moderate to severe non-segmental vitiligo. EB06 works by binding to chemokine ligand 10 (CXCL10), which is associated with the disease's progression. This approval marks a significant milestone for Edesa, potentially enhancing partnerships and advancing its development pipeline.
Edesa Biotech announced promising topline results from a Phase 2b clinical trial evaluating the 1.0% EB01 cream for moderate-to-severe allergic contact dermatitis (ACD). The trial, involving 200 subjects, showed that the 1.0% formulation achieved a statistically significant 60% average improvement in symptoms compared to 39% for the placebo (p=0.02) at day 29. Additionally, 53% of patients treated with EB01 reached 'clear' or 'almost clear' skin, versus 29% in the placebo group (p=0.04). No serious treatment-related adverse events were reported. Edesa plans to meet with the FDA for an End of Phase 2 discussion following a complete analysis expected mid-2023.
Edesa Biotech (Nasdaq:EDSA) has received Fast Track designation from the FDA for its monoclonal antibody candidate EB05, aimed at treating Acute Respiratory Distress Syndrome (ARDS)/b) in hospitalized Covid-19 patients. This designation facilitates accelerated communication with the FDA and potential faster regulatory approval. Positive Phase 2 trial results showed an in mortality risk for patients receiving EB05 compared to a placebo. The Fast Track program aims to address serious diseases and unmet medical needs.
Edesa Biotech, Inc. (NASDAQ:EDSA) reported its financial results for the fiscal year ending September 30, 2022. The company achieved an 84% reduction in the risk of death for critically ill COVID-19 patients receiving its monoclonal antibody, EB05. Total operating expenses fell over 20% to $18.37 million, with a net loss of $17.55 million for the year. Edesa reported cash and cash equivalents of $7.09 million as of September 30. The company has ongoing Phase 3 clinical protocol reviews and anticipates significant progress in 2023.
Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical firm, announced Dr. Par Nijhawan's participation in the panel discussion at the Cantor Fitzgerald Medical Dermatology, Ophthalmology & Medtech Conference on December 8, 2022, at 10:00 am ET. Meetings can be arranged through Cantor representatives or directly at investors@edesabiotech.com. Edesa is focused on treatments for immune-related diseases, with lead candidates EB01 (Phase 2b) for allergic contact dermatitis and EB05 (Phase 3) for Acute Respiratory Distress Syndrome.
Edesa Biotech (NASDAQ:EDSA) announced the closing of a $3.0 million private placement priced at-the-market. The offering included 2,691,337 common shares, alongside 12-month and 3-year warrants for an additional 1,345,665 shares each. The common shares were sold at $1.125 each. Proceeds will support clinical programs, including a Phase 2b study for allergic contact dermatitis. Notably, officers and directors invested approximately $0.5 million in this offering. This transaction is registered under Section 4(a)(2) of the Securities Act.
Edesa Biotech reported favorable final results from the Phase 2 study of its monoclonal antibody candidate EB05 for treating Covid-19 induced ARDS. The study demonstrated an 84% reduction in mortality risk at 28 days for critically ill patients receiving EB05 compared to placebo (7.7% vs. 40%, p=0.04). A Clinical Study Report has been submitted to the FDA, and the company is advancing to Phase 3 trials.
EB05 may address significant unmet needs in ARDS treatment caused by various pathogens. The study was partially funded by a C$14 million government grant.
Edesa Biotech (NASDAQ:EDSA) announced that CEO Par Nijhawan will present at the H.C. Wainwright Global Investment Conference in New York from September 12-14, 2022. The presentation is scheduled for September 12 at 10:00 am Eastern Time, and slides will be available on the Edesa website. Edesa is focused on developing treatments for inflammatory diseases, with key products, EB05 for ARDS and EB01 for chronic allergic contact dermatitis, in late-stage studies.
Edesa Biotech (NASDAQ:EDSA) has completed patient recruitment for its Phase 2b clinical study of EB01, a non-steroidal anti-inflammatory drug candidate for moderate-to-severe chronic Allergic Contact Dermatitis. The primary endpoint is expected to be reached within 30 days, with topline data anticipated by year-end. The company is exploring out-licensing opportunities outside North America and prioritizing future clinical studies for EB01. Interim results show promising efficacy, with significant differences reported in key endpoints compared to placebo, and no serious adverse events were recorded.